Comparative crossover, randomized, open-label bioequivalence study on the bioequivalence of two formulations of thioctic acid in healthy volunteers

Clinical and Experimental Hypertension

Volumn 29, Issue 8, 2007, Pages 575-586

  Mignini, Fiorenzo ^a   Streccioni, Valentino ^a   Tomassoni, Daniele ^a   Traini, Enea ^a   Amenta, Francesco ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Antioxidant; Bioequivalence; Thioctic acid

Indexed keywords

THIOCTIC ACID; TIOCTIL N; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; THIOCTIC ACID;

EID: 36849075192     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960701744111     Document Type: Article

References (45)

1. Snell EE, Strong FM, Peterson WH. Growth factors for bacteria VI: Fractionation and properties of an accessory factor for lactic acid bacteria. Biochem J. 1937;31:1789-1799.
2. Reed LJ. Multienzyme complexes. Acc Chem Res. 1974;7:40.
3. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995;19:227-250.
4. Scholich H, Murphy ME, Sies H. Antioxidant activity of dihydrolipoate against microsomal lipid peroxidation and its dependence on alpha-tocopherol. Biochim Biophys Acta. 1989;1001:256-261.
5. Busse E, Zimmer G, Schopohl B, Kornhuber B. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung. 1992;42:829-831.
6. Kagan VE, Serbinova EA, Koynova GM, Kitanova SA, Tyurin VA, Stoytchev TS, Quinn PJ, Packer L. Antioxidant action of ubiquinol homologues with different isoprenoid chain length in biomembranes. Free Radic Biol Med. 1990;9:117-126.
7. Jorg J, Metz F, Scharafinski H. Drug treatment of diabetic polyneuropathy with alpha-lipoic acid or vitamin B preparations. A clinical and neurophysiologic study. Nervenarzt 1988;59:36-44.
8. Ziegler D, Mayer P, Muehlen H, Gries FA. Effekte einer Therapie mit alpha- Liponsaeure gegenueber Vitamin B1 bei der diabetischen Neuropathie. Diabetes Stoffw. 1993;2:443.
9. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A three-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38:1425-1433.
10. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia. 1997;40:647-653.
11. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A four-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20:369-373.
12. Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 1997;46:S62-S66.
13. Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med, 1999;26:1495-1500.
14. Haak ES, Usadel KH, Kohleisen M, et al. The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res. 1999;58:28-34.
15. Rehman A, Nourooz-Zadeh J, Moller W, et al. Increased oxidative damage to all DNA bases in patients with type II diabetes. FEBS Lett. 1999;448:120-122.
16. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A seven-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22:1296-1301.
17. Gleiter CH, Schung BS, Hermann R, Elze M, Blume HH, Guntert-Remy U. Influence of food intake on the bioavailability of thioctic acid enantiomers. Eur J Clin Pharmacaol. 1996;50:513-514.
18. Hermann R, Niebch G, Borbe HO, et al. Enantioselective pharmacokinetics and bioavailability of different racemic alpha-lipoic acid formulations in healthy volunteers. Eur J Clin Pharmacol Sci. 1996;4:167.
19. Teichert J, Kern J, Tritschler HJ, Ulrich H, Preiss R. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther. 1998;36:625-628.
20. Breithaupt-Grögler K, Niebch G, Schneider E, et al. Dose-proportionality of oral thioctic acid - coincidence of assessments via pooled plasma and individual data. Eur J Clin Pharmacol Sci. 1999;8:57-65.
21. World Medical Association Declaration of Helsinki. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Available at: http://www.idi.it/ ric/ce/helsinki.pdf.
22. European Agency for the Evaluation of Medical Products, Committee for Proprietary Medical Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London; 2001.
23. FDA Guidance for Industry, Statistical Approaches to Establishing Bioequivalence. Washington, DC: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research CDER; 2001.
24. Chen J, Jiang W, Cai J, Tao W, Gao X, Jiang X. Quantification of lipoic acid in plasma by highperformance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Sep;824:249-257.
25. Hodges JR, Lehmann EL. Annals of Mathematical Statistics. 1963;34:598-611.
26. Phillips KF. Power of the two one-sided tests procedure in bioequivalence. Journal Pharmacokinet Biopharm. 1990;18(2):137-144.
27. Sauter R, Steinijans VW, Diletti E, Bohm A, Schulz HU. Presentation of results from bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1992;30(7):233-256.
28. Chow SC, Liu JP. Desigend and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcell Dekker Inc; 1992.
29. Tschudi MR, Luscher TF. Nitric oxide: The endogenous nitrate in the cardiovascular system. Herz. 1996;21:50-60.
30. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
31. Noll G, Tschudi M, Nava E, Luscher TF. Endothelium and high blood pressure. Int J Microcirc Clin Exp. 1997;17:273-279.
32. Pechanova O, Kashiba M, Inoue M. Role of glutathione in stabilization of nitric oxide during hypertension developed by inhibition of nitric oxide synthase in the rat. Jpn J Pharmacol. 1999;81:223-229.
33. Zicha J, Dobesova Z, Kunes J. Relative deficiency of nitric oxide-dependent vasodilation in salt-hypertensive Dahl rats: The possible role of superoxide anions. J Hypertens. 2001;19:247-254.
34. Kunes J, Hojna S, Kadlecova M, Dobesova Z, Rauchova H, Vokurkova M, Loukotova J, Pechanova O, Zicha J. Altered balance of vasoactive systems in experimental hypertension: The role of relative NO deficiency. Physiol Res. 2004;53:S23-S34.
35. Pechanova O, Rezzani R, Babal P, Bernatova I, Andriantsitohaina R. Beneficial effects of provinols: Cardiovascular system and kidney. Physiol Res. 2006;55:S17-S30.
36. de Champlain J, Wu R, Girouard H, Karas M, El Midaoui A, Laplante MA, Wu L. Oxidative stress in hypertension. Clin Exp Hypertens. 2004;26:593-601.
37. Chen X, Touyz RM, Park JB, Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension. 2001;38:606-611.
38. Chu Y, Iida S, Lund DD, Weiss RM, DiBona GF, Watanabe Y, Faraci FM, Heistad DD. Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: Role of heparin-binding domain. Circ Res. 2003;92:461-468.
39. Kojsova S, Jendekova L, Zicha J, Kunes J, Andriantsitohaina R, Pechanova O. The effect of different antioxidants on nitric oxide production in hypertensive rats. Physiol Res. 2006;55:S3-S16.
40. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary lipoic acid supplementation prevents fructose-induced hypertension in rats. Nutr Metab Cardiovasc Dis. 2000;10:339-346.
41. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens. 2000;18:567-573.
42. Vasdev S, Gill V, Longerich L, Parai S, Gadag V. Salt-induced hypertension in WKY rats: Prevention by alpha-lipoic acid supplementation. Mol Cell Biochem. 2003;254:319-326.
43. Wollin SD, Jones PJ. Alpha-lipoic acid and cardiovascular disease. J Nutr. 2003;Nov;133:3327-3330.
44. Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Munch G. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther. 2007 Jan;113:154-164.
45. Pershadsingh HA. Alpha-lipoic acid: Physiologic mechanisms and indications for the treatment of metabolic syndrome. Expert Opin Investig Drugs. 2007 Mar;16:291-302.